A Phase 1 Study to Assess the Safety, Tolerability and PK of ARRY-380-an Oral Inhibitor of ErbB2
Abstract
ARRY-380, dosed BID as powder-in-capsule (PiC) formulation, displayed an acceptable PK profile in cancer patients. At doses ≥ 200 mg BID, 8/10 HER2+ patients had tumor regressions and, of these 8 patients, 4 received therapy for ≥16 weeks.
This is an open access poster distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
